
Matthew Stevenson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7881599/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Reductions in biomarkers of exposure to selected harmful and potentially harmful constituents following exclusive and partial switching from combustible cigarettes to mybluâ,,¢ electronic nicotine delivery systems (ENDS). Internal and Emergency Medicine, 2022, 17, 397-410.	1.0	19
2	Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes to Predict the Cardiotoxicity Potential of Next Generation Nicotine Products. Frontiers in Toxicology, 2022, 4, 747508.	1.6	4
3	Preclinical Assessment of Tobacco-Free Nicotine Pouches Demonstrates Reduced <i>In Vitro</i> Toxicity Compared with Tobacco Snus and Combustible Cigarette Smoke. Applied in Vitro Toxicology, 2022, 8, 24-35.	0.6	10
4	A randomised, open-label, cross-over clinical study to evaluate the pharmacokinetic, pharmacodynamic and safety and tolerability profiles of tobacco-free oral nicotine pouches relative to cigarettes. Psychopharmacology, 2022, 239, 2931-2943.	1.5	8
5	Acute electronic vapour product whole aerosol exposure of 3D human bronchial tissue results in minimal cellular and transcriptomic responses when compared to cigarette smoke. Toxicology Research and Application, 2021, 5, 239784732098849.	0.7	5
6	Use of a rapid human primary cell-based disease screening model, to compare next generation products to combustible cigarettes. Current Research in Toxicology, 2021, 2, 309-321.	1.3	3
7	Multi-endpoint analysis of human 3D airway epithelium following repeated exposure to whole electronic vapor product aerosol or cigarette smoke. Current Research in Toxicology, 2021, 2, 99-115.	1.3	13
8	The <i>in vitro</i> ToxTracker and Aneugen Clastogen Evaluation extension assay as a tool in the assessment of relative genotoxic potential of e-liquids and their aerosols. Mutagenesis, 2021, 36, 129-142.	1.0	12
9	A comparative in vitro toxicity assessment of electronic vaping product e-liquids and aerosols with tobacco cigarette smoke. Toxicology in Vitro, 2020, 66, 104866.	1.1	30
10	The use of human induced pluripotent stem cells to screen for developmental toxicity potential indicates reduced potential for non-combusted products, when compared to cigarettes. Current Research in Toxicology, 2020, 1, 161-173.	1.3	10
11	Chemical Composition and <i>In Vitro</i> Toxicity Profile of a Pod-Based E-Cigarette Aerosol Compared to Cigarette Smoke. Applied in Vitro Toxicology, 2020, 6, 11-41.	0.6	31
12	The use of Genomic Allergen Rapid Detection (GARD) assays to predict the respiratory and skin sensitising potential of e-liquids. Regulatory Toxicology and Pharmacology, 2019, 103, 158-165.	1.3	8
13	High Content Screening in NHBE cells shows significantly reduced biological activity of flavoured e-liquids, when compared to cigarette smoke condensate. Toxicology in Vitro, 2019, 58, 86-96.	1.1	16
14	Toxicological comparison of cigarette smoke and e-cigarette aerosol using a 3D in vitro human respiratory model. Regulatory Toxicology and Pharmacology, 2019, 103, 314-324.	1.3	64